About ADC Therapeutics
ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with our next-generation, targeted antibody drug conjugates (ADCs). With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, we are working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors.
Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC). Our highly skilled global team is committed to confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.
For more information, please visit https://www.adctherapeutics.com/ and follow us on Twitter @adctherapeutics.
|
|
|
201-500 employees
View all ADC Therapeutics employees
|
|
Biotechnology
|
|
Lausanne, Vaud, Switzerland, CH
|
ADC Therapeutics Alternatives
Frequently Asked Questions about ADC Therapeutics
The decision makers in ADC Therapeutics are Andrea Piper, Christopher Keir, David Ellis, etc. Click to Find ADC Therapeutics decision makers emails.
ADC Therapeutics Staff Directory
Search ADC Therapeutics Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
